Formulations comprising selective androgen receptor modulators

A pharmaceutical composition comprising:

• a selective androgen receptor modulator (SARM) compound having in-vivo androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor, said compound represented by the structure of formula I:
• wherein
• X is O, CH2, NH, Se, PR, NO or NR;
• T is OH, OR, —NHCOCH3, or NHCOR;
• Z is NO2, CN, COOH, COR, NHCOR or CONHR;
• Y is CF3, F, I, Br, Cl, CN, CR3 or SnR3;
• Q is alkyl, halogen, CF3, CN CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, SR;
• or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
• R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH;
• and
• R1 is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3;
• a pharmaceutically acceptable carrier or diluent;
• a flow-aid;
• and
• a lubricant.

A pharmaceutical composition comprising:

• a selective androgen receptor modulator (SARM) compound having in-vivo androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor, said compound represented by the structure of formula I:
• wherein
• X is O, CH2, NH, Se, PR, NO or NR;
• T is OH, OR, —NHCOCH3, or NHCOR;
• Z is NO2, CN, COOH, COR, NHCOR or CONHR;
• Y is CF3, F, I, Br, Cl, CN, CR3 or SnR3;
• Q is alkyl, halogen, CF3, CN CR3, SnR3, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, SR;
• or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
• R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl or OH;
• and
• R1 is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3;
• lactose monohydrate;
• microcrystalline cellulose;
• magnesium stearate;
• and
• silicon dioxide.